Hillevax Inc
HLVX2.060USD
+0.020+0.98%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
103.21MCap. mercado
PérdidaP/E TTM
Más Datos de Hillevax Inc Compañía
HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The Company's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-216 includes six common norovirus genotypes, GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
Información de la empresa
Símbolo de cotizaciónHLVX
Nombre de la empresaHillevax Inc
Fecha de salida a bolsaApr 29, 2022
Director ejecutivoDr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Número de empleados14
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 29
Dirección321 Harrison Ave, Suite 500
CiudadBOSTON
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02118
Teléfono16172135054
Sitio Webhttps://www.hillevax.com/
Símbolo de cotizaciónHLVX
Fecha de salida a bolsaApr 29, 2022
Director ejecutivoDr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
876.86K
+11.51%
Mr. Jaime Sepulveda, M.D.
Mr. Jaime Sepulveda, M.D.
Independent Director
Independent Director
59.22K
+40.93%
Ms. Jeryl Hilleman
Ms. Jeryl Hilleman
Independent Director
Independent Director
59.22K
+40.93%
Mr. Shane Maltbie, CPA
Mr. Shane Maltbie, CPA
Chief Financial Officer
Chief Financial Officer
38.30K
-52.06%
Dr. Gary Dubin, M.D.
Dr. Gary Dubin, M.D.
Independent Director
Independent Director
17.20K
--
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Lead Independent Director
Lead Independent Director
17.20K
--
Dr. Nanette Cocero, Ph.D.
Dr. Nanette Cocero, Ph.D.
Independent Director
Independent Director
17.20K
--
Dr. Shelley Chu, M.D., Ph.D.
Dr. Shelley Chu, M.D., Ph.D.
Independent Director
Independent Director
17.20K
--
Dr. Aditya Kohli, Ph.D.
Dr. Aditya Kohli, Ph.D.
Director
Director
--
--
Dr. Julie Louise Gerberding, M.D.
Dr. Julie Louise Gerberding, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
876.86K
+11.51%
Mr. Jaime Sepulveda, M.D.
Mr. Jaime Sepulveda, M.D.
Independent Director
Independent Director
59.22K
+40.93%
Ms. Jeryl Hilleman
Ms. Jeryl Hilleman
Independent Director
Independent Director
59.22K
+40.93%
Mr. Shane Maltbie, CPA
Mr. Shane Maltbie, CPA
Chief Financial Officer
Chief Financial Officer
38.30K
-52.06%
Dr. Gary Dubin, M.D.
Dr. Gary Dubin, M.D.
Independent Director
Independent Director
17.20K
--
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Lead Independent Director
Lead Independent Director
17.20K
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mar., 29 de jul
Actualizado: mar., 29 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Frazier Life Sciences Management, L.P.
21.17%
Takeda Pharmaceutical Co Ltd
13.41%
Tang Capital Management, LLC
9.81%
EcoR1 Capital, LLC
5.77%
Lightspeed Venture Partners
4.59%
Other
45.24%
Accionistas
Accionistas
Proporción
Frazier Life Sciences Management, L.P.
21.17%
Takeda Pharmaceutical Co Ltd
13.41%
Tang Capital Management, LLC
9.81%
EcoR1 Capital, LLC
5.77%
Lightspeed Venture Partners
4.59%
Other
45.24%
Tipos de accionistas
Accionistas
Proporción
Private Equity
22.82%
Hedge Fund
16.80%
Investment Advisor/Hedge Fund
15.22%
Corporation
13.41%
Investment Advisor
11.56%
Venture Capital
9.11%
Individual Investor
3.71%
Research Firm
1.02%
Bank and Trust
0.08%
Other
6.27%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
224
44.13M
88.00%
-14.24M
2025Q1
229
46.31M
92.39%
-14.77M
2024Q4
226
47.12M
94.62%
-13.67M
2024Q3
218
46.00M
92.53%
-13.52M
2024Q2
202
49.77M
100.23%
-2.02M
2024Q1
182
48.47M
97.79%
-558.66K
2023Q4
166
46.57M
96.99%
+4.81M
2023Q3
161
39.77M
86.30%
+8.72M
2023Q2
146
30.99M
80.52%
+1.24M
2023Q1
140
32.25M
85.25%
+3.76M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Frazier Life Sciences Management, L.P.
10.62M
21.17%
--
--
Mar 31, 2025
Takeda Pharmaceutical Co Ltd
6.72M
13.41%
--
--
Mar 31, 2025
Tang Capital Management, LLC
4.92M
9.81%
--
--
May 02, 2025
Lightspeed Venture Partners
2.30M
4.59%
-37.51K
-1.60%
Mar 31, 2025
Franklin Advisers, Inc.
1.95M
3.9%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.92M
3.82%
-70.63K
-3.56%
Mar 31, 2025
Deerfield Management Company, L.P.
1.88M
3.75%
--
--
Mar 31, 2025
Abingworth Management Limited
1.84M
3.67%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.59M
3.16%
-20.50K
-1.28%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
Fidelity MSCI Health Care Index ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Global X Russell 2000 ETF
0%
Avantis Responsible US Equity ETF
0%
iShares Russell 2000 Value ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Ver más
iShares Micro-Cap ETF
Proporción0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Proporción0%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0%
Fidelity MSCI Health Care Index ETF
Proporción0%
Fidelity Nasdaq Composite Index ETF
Proporción0%
Global X Russell 2000 Covered Call ETF
Proporción0%
Global X Russell 2000 ETF
Proporción0%
Avantis Responsible US Equity ETF
Proporción0%
iShares Russell 2000 Value ETF
Proporción0%
ProShares Ultra Nasdaq Biotechnology
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
